Mucormycosis; Pulmonary (Etiology)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Mucormycosis; Pulmonary (Etiology) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT05468372

Amphotericin Versus Posaconazole for Pulmonary Mucormycosis

Pulmonary mucormycosis is a serious illness with high morbidity and mortality (approximately 57%). Surgery and antifungal therapy are central in the management…

India50 participantsStarted 2022-07-01

Treatment: Posaconazole 600 mg followed by posaconazole 300 mg once daily, Liposomal Amphotericin B

All recent trials (2 shown)

CompletedPhase 1/2

NCT06267326

World Health Organization (WHO) , COVID19 Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt

Objectives: identify and recognize clinical Characteristics, Pathophysiology, and management of a group of patients with rhino Rhino-Orbito-Cerebral Mucormycosi…

Egypt35 participantsStarted 2021-05-23

Treatment: debridment